In silico and in vitro metabolism of ribociclib: a mass spectrometric approach to bioactivation pathway elucidation and metabolite profiling

Ribociclib (RBC, Kisqali®) is a highly selective CDK4/6 inhibitor that has been approved for breast cancer therapy. Initially, prediction of susceptible sites of metabolism and reactivity pathways were performed by the StarDrop WhichP450™ module and the Xenosite web predictor tool, respectively. Lat...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsubi, Thamer A., Attwa, Mohamed W., Bakheit, Ahmed H., Darwish, Hany W., Abuelizz, Hatem A., Kadi, Adnan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2020
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054585/
https://www.ncbi.nlm.nih.gov/pubmed/35514564
http://dx.doi.org/10.1039/d0ra01624a

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054585/
https://www.ncbi.nlm.nih.gov/pubmed/35514564
http://dx.doi.org/10.1039/d0ra01624a

Ejemplares similares